Table 3 Cumulative effects of selected SNPs on HCV infection outcomes
a) Combined favorable alleles (rs1063478–T and rs2284191–G) and anti–HCV | |||
|---|---|---|---|
Variables | Uninfected N(%) | Infected N(%) | OR (95% CI) |
0–1 | 37 (7.7) | 75 (10.0) | 1.00 |
2 | 227 (47.1) | 364 (48.4) | 0.62 (0.37–1.03) |
3 | 188 (39.0) | 245 (32.6) | 0.46 (0.27–0.78) |
4 | 30 (6.2) | 41 (9.0) | 0.50 (0.24–1.04) |
Trend | P a = 0.037 | ||
0–2 | 264 (54.8) | 439 (58.4) | 1.00 |
3–4 | 218 (45.2) | 286 (41.6) | 0.70 (0.53–0.93) |
b) Combined favorable alleles (rs17587–A and rs7383287–G) and HCV chronicity | |||
Variables | Resolver N(%) | Chronic N(%) | OR (95% CI) |
0 | 71 (36.8) | 257 (48.3) | 1.00 |
1 | 62 (32.1) | 177 (33.3) | 0.79 (0.53–1.77) |
2 | 50 (25.9) | 74 (13.9) | 0.42 (0.26–0.66) |
3–4 | 10 (5.2) | 23 (4.5) | 0.62 (0.27–1.37) |
Trend | P a = 0.001 | ||
0 | 71 (36.8) | 257 (48.3) | 1.00 |
1–4 | 122 (63.2) | 275 (51.7) | 0.63 (0.45–0.88) |